Veterinary Therapeutic Protein and Peptide Discovery

Veterinary therapeutic proteins and peptides exhibit great potential for treating a diverse array of animal diseases, characterized by their precise targeting and minimal side effects. At BioVenic, we leverage our expertise to develop safe and effective solutions, pushing the boundaries of veterinary medicine. Our extensive experience in biotechnology forms the robust foundation of our specialized services, focusing on the discovery and optimization of therapeutic proteins and peptides. This enables us to offer innovative, tailored solutions to meet our client's specific needs, ensuring optimal animal health outcomes.

Veterinary Therapeutic Protein and Peptide Discovery Services

BioVenic offers specialized veterinary therapeutic protein and peptide discovery services, including phage display, ribosomal display, mRNA display, DNA display, bacterial display, yeast display, cell display, high throughput screening, and rational design for the discovery of veterinary therapeutic proteins and peptides. These platforms enable us to support our clients in the discovery and development of innovative veterinary therapeutic proteins and peptides, ultimately enhancing animal health care.

Phage Display Platform

Phage display technology is used for in vitro screening of high-affinity ligands, selecting specific and effective candidate molecules from numerous protein or peptide sequences. BioVenic utilizes a specialized phage display platform for veterinary therapeutic proteins and peptides, providing targeted library construction and screening services to meet client needs.

Fig.1 Process for screening cell-specific peptides from phage display libraries. ^1,2

Ribosomal Display Platform

Ribosomal display platform is an advanced in vitro cell-free system capable of generating protein and peptide with exceptional diversity up to 10¹⁵. This platform leverages proprietary prokaryotic and eukaryotic display technologies. BioVenic has developed a unique ribosome display platform that delivers veterinary therapeutic proteins and peptides characterized by high affinity and minimal side effects, assisting clients in completing their projects.

Fig.2 Preparation of ribosome display construct and principle of ribosomal display selection. ^3,4

mRNA Display Platform

mRNA display is a potent technique in molecular biology for the in vitro selection and evolution of proteins and peptides. It creates extensive libraries of proteins and peptides linked to their corresponding mRNA sequences, enabling the direct selection of therapeutic proteins and peptides with desired properties. BioVenic provides a comprehensive one-stop service for veterinary therapeutic protein and peptide engineering through mRNA display, facilitating innovative discoveries.

Fig.3 A typical mRNA display selection cycle.^7,8

DNA Display Platform

DNA display is an innovative technique in molecular biology used for protein and peptide engineering. Both methods involve linking proteins or peptides to their corresponding DNA sequences, but they differ in the linkage. BioVenic has developed a non-covalent DNA display platform to help clients screen the veterinary proteins and peptides with desired properties.

Fig.4 Schematic representation of DNA display selection of peptide ligands. ^9,10

Bacterial Display Platform

Bacterial display, or bacterial surface display is a sophisticated technique for protein and peptide engineering that is widely employed for in vitro discovery of these biomolecules. This innovative method correlates the function of proteins or peptides with the genes that encode them. It involves creating extensive libraries that contain billions of diverse polypeptides displayed on the surface of bacteria, which are then screened for specific properties. BioVenic offers a unique bacterial display technology specifically tailored for the discovery of veterinary therapeutic proteins and peptides.

Fig.5 Bacterial display library screening. ^11,12

Yeast Display Platform

Yeast display or yeast surface display is a cutting-edge technique extensively used to express the proteins or peptides at the yeast surface following translation and maturation in a eukaryotic system. BioVenic has pioneered a unique yeast display platform specifically designed for the isolation and engineering of veterinary therapeutic proteins and peptides.

Fig.6 Schematic illustration of yeast surface display based on S. cerevisiae strain EBY100. ^3,5

Mammalian Cell Display Platform

Mammalian cell display is a robust technology employed in biotechnology and bioengineering for the discovery and optimization of proteins and antibodies. This method involves expressing libraries of protein variants on the surface of mammalian cells, enabling the selection of proteins with desired characteristics via cell sorting techniques such as flow cytometry. BioVenic provides comprehensive services for the discovery of veterinary therapeutic proteins and peptides, assisting clients in advancing their research and development efforts.

Fig.7 Schematic representation of mammalian surface display. ^3,6

Integrated Venomics Platform

Venoms are extensive natural libraries filled with bioactive molecules, each with potential therapeutic uses. Invertebrate venoms mainly consist of peptides targeting specific ion channels and receptors, while snake venoms contain diverse proteins, opening new therapeutic avenues. BioVenic has developed an integrated venomics platform to discover veterinary therapeutic proteins and peptides. Using next-generation sequencing, bioinformatics, and advanced transcriptomic and proteomic methods, we provide services to identify, characterize, and optimize venom-derived proteins and peptides for veterinary use.

Fig.8 Schematic representation of Integrated Venomics Platform. ^13,14

High Throughput Screening

High Throughput Screening (HTS) is crucial in biotechnology and pharmaceutical research for quickly assessing numerous protein and peptide candidates for their therapeutic potential. This technique uses automated systems and specialized equipment to perform multiple biochemical, genetic, or pharmacological tests efficiently. HTS allows the screening of extensive libraries of proteins and peptides to identify those with desirable traits like binding affinity or biological activity, essential for drug development and therapeutic applications. BioVenic provides a full range of high-throughput screening services tailored to assist clients in discovering veterinary proteins and peptides.

Fig.9 Protein microarray experimental procedure. ^15,16

Rational Design

A multitude of protein-protein interactions (PPIs) are essential for cellular functions. Peptides can either inhibit or activate these PPIs, providing higher specificity and lower toxicity than traditional drugs. By leveraging in-depth knowledge of the molecular structures of target proteins, BioVeinc offers a rational design platform that speeds up the discovery of veterinary therapeutic proteins and peptides. Our team employs advanced computational modeling and bioinformatics to effectively identify interaction sites and mechanisms.

Fig.10 Comparison of a computational in silico pipeline versus traditional high throughput wet-lab approach for designing therapeutic peptides: steps and timelines.^17,18

Veterinary Therapeutic Protein and Peptide Discovery Service Workflow

Our services include initial consultation, solution proposal, contract signing, service execution, and delivery & reporting. We are committed to advancing new veterinary therapeutic proteins and peptides through innovative research and collaborative efforts for our clients.

Fig.11 The service workflow of veterinary therapeutic protein and peptide discovery. (BioVenic Original)

Why Choose Us?

Fig.12 The advantages of veterinary therapeutic protein and peptide discovery services. (BioVenic Original)

Veterinary therapeutic protein and peptide discovery involves identifying proteins and peptides with potential therapeutic value from diverse biological sources. BioVenic offers specialized discovery services in this area, leveraging advanced technology and extensive experience to support clients in developing new veterinary therapeutic proteins and peptides tailored to their needs. If you are interested in these services, please contact us.

References

1. Wu, Chien-Hsun, et al. "Advancement and applications of peptide phage display technology in biomedical science." Journal of Biomedical Science 23.1 (2016): 1-14.
2. Image retrieved from Figure 3 "The working principle for screening of cell-specific peptides from a phage display library". Wu, Chien-Hsun, et al., 2016, used under CC BY 4.0, the title was changed to "Process for screening cell-specific peptides from phage display libraries".
3. Valldorf, Bernhard, et al. "Antibody display technologies: selecting the cream of the crop." Biological Chemistry 403.5-6 (2022): 455-477.
4. Image retrieved from Figure 5 "Principle of ribosome display". Valldorf, Bernhard, et al., 2022, used under CC BY 4.0, the title was changed to "Preparation of ribosome display construct and principle of ribosomal display selection".
5. Image retrieved from Figure 3 "Overview of yeast surface display". Valldorf, Bernhard, et al., 2022, used under CC BY 4.0, the title was changed to " Schematic illustration of yeast surface display based on S. cerevisiae strain EBY100".
6. Image retrieved from Figure 4 "Schematic representation of mammalian surface display". Valldorf, Bernhard, et al., 2022, used under CC BY 4.0, the title was changed to " Schematic representation of mammalian surface display".
7. Hammond, Philip W., et al. "In vitro selection and characterization of Bcl-XL-binding proteins from a mix of tissue-specific mRNA display libraries." Journal of Biological Chemistry 276.24 (2001): 20898-20906.
8. Image retrieved from Figure 1 "Iterative selection using mRNA display". Hammond, Philip W., et al., used under CC BY 4.0, the title was changed to "A typical mRNA display selection cycle".
9. Doi, Nobuhide, et al. "DNA display selection of peptide ligands for a full-length human G protein-coupled receptor on CHO-K1 cells." PloS one 7.1 (2012): e30084.
10. Image retrieved from Figure 1 "Schematic representation of DNA display selection of peptide ligands for GPCR expressed on cells". Doi, Nobuhide, et al., used under CC BY 4.0, the title was changed to "Schematic representation of DNA display selection of peptide ligands".
11. Dong, Bing, et al. "Peptide-fluorescent bacteria complex as luminescent reagents for cancer diagnosis." Plos one 8.1 (2013): e54467
12. Image retrieved from Figure 1 "The process of screening and enriching the binding peptide library for cancer cells with bacteria surface display methods". Dong, Bing, et al., used under CC BY 4.0. The original image was modified by extracting and using only part A the title was changed to "Bacterial display library screening".
13. Gorson, J., and M. Holford. "Small packages, big returns: uncovering the venom diversity of small invertebrate conoidean snails." Integrative and Comparative Biology (2016): 962-972.
14. Image retrieved from Figure 2 "Venomics: an integrated NGS and proteomic strategy". Gorson, J., and M. Holford., 2016, used under CC BY 4.0, the title was changed to "Schematic representation of Integrated Venomics Platform".
15. Matei, Clara, et al. "Protein microarray for complex apoptosis monitoring of dysplastic oral keratinocytes in experimental photodynamic therapy." Biological research 47 (2014): 1-9.
16. Image retrieved from Figure 2 "Protein microarray technology principle". Matei, Clara, et al., 2014, used under CC BY 4.0, the title was changed to " Protein microarray experimental procedure".
17. Nissan, Nour, et al. "Future Perspective: Harnessing the Power of Artificial Intelligence in the Generation of New Peptide Drugs." Biomolecules 14.10 (2024): 1303.
18. Image retrieved from Figure 2 "Comparison of a computational in silico pipeline vs. traditional high throughput wet-lab approach for designing therapeutic peptides: steps and timelines". Nissan, Nour, et al., 2024, used under CC BY 4.0, the title was changed to " Comparison of a computational in silico pipeline versus traditional high throughput wet-lab approach for designing therapeutic peptides: steps and timelines".